Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;18(6):670-7.
doi: 10.1177/1087057112469406. Epub 2012 Dec 4.

Identification of small-molecule agonists of human relaxin family receptor 1 (RXFP1) by using a homogenous cell-based cAMP assay

Catherine Z Chen  1 , Noel Southall, Jingbo Xiao, Juan J Marugan, Marc Ferrer, Xin Hu, Raisa E Jones, Shu Feng, Irina U Agoulnik, Wei Zheng, Alexander I Agoulnik
Affiliations

Identification of small-molecule agonists of human relaxin family receptor 1 (RXFP1) by using a homogenous cell-based cAMP assay

Catherine Z Chen et al. J Biomol Screen. 2013 Jul.

Abstract

The relaxin hormone is involved in a variety of biological functions, including female reproduction and parturition, as well as regulation of cardiovascular, renal, pulmonary, and hepatic functions. It regulates extracellular matrix remodeling, cell invasiveness, proliferation, differentiation, and overall tissue homeostasis. The G protein-coupled receptor (GPCR) relaxin family receptor 1 (RXFP1) is a cognate relaxin receptor that mainly signals through cyclic AMP second messenger. Although agonists of the receptor could have a wide range of pharmacologic utility, until now there have been no reported small-molecule agonists for relaxin receptors. Here, we report the development of a quantitative high-throughput platform for an RXFP1 agonist screen based on homogenous cell-based HTRF cyclic AMP (cAMP) assay technology. Two small molecules of similar structure were independently identified from a screen of more than 365 677 compounds. Neither compound showed activity in a counterscreen with HEK293T cells transfected with an unrelated GPCR vasopressin 1b receptor. These small-molecule agonists also demonstrated selectivity against the RXFP2 receptor, providing a basis for future medicinal chemistry optimization of selective relaxin receptor agonists.

Keywords: GPCR; RXFP1; agonist; qHTS; relaxin; small molecule.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1. Assay miniaturization and validation
Concentration responses for (a) relaxin and (b) forskolin in HEK293-RXFP1 cells. Assays were performed in 384-well and 1,536-well formats using the HTRF cAMP assay kit. 100% activity was normalized as 57.7 μM forskolin stimulation and 0% activity was normalized as 0.58% DMSO controls. (c) HTRF signal from 0.57% DMSO, 28.75 nM relaxin and 57.5 μM forskolin treatments in HEK293-RXFP1 cells. Mean and standard deviations were calculated from 12 treatment wells in 384-well assay format. (d) Scatter plot of the ratiometric signal from a 1,536-well DMSO plate to establish assay performance parameters. Column 1 was treated with a relaxin titration (24.9 pM – 1.47 μM), columns 2 and 3 received DMSO, and column 4 received 125 nM relaxin.
Figure 2
Figure 2
Summary of qHTS and follow up assays.
Figure 3
Figure 3. Concentration response of human RXFP1 agonists
HTRF cAMP response in HEK293-RXFP1 (black), HEK293-RXFP2 (blue) and HEK293-V1b (green) cell lines and per cent viability (gray) for (a) relaxin, (b), forskolin, (c) MLS000579461 and (d) MLS000088899. (e) Concentration response of MLS000579461 and MLS000088899 in ELISA cAMP assay. (f) Structures of the two lead compounds. Cyclic AMP activities of compounds were normalized to the maximal response of forskolin (57.5 μM) as 100% activity and DMSO control (0.58% DMSO) as 0% activity.
See this image and copyright information in PMC

References

    1. Kong RC, Shilling PJ, Lobb DK, Gooley PR, Bathgate RA. Membrane receptors: structure and function of the relaxin family peptide receptors. Mol Cell Endocrinol. 2010;320(1–2):1–15. - PubMed
    1. Van Der Westhuizen ET, Summers RJ, Halls ML, Bathgate RA, Sexton PM. Relaxin receptors--new drug targets for multiple disease states. Curr Drug Targets. 2007;8(1):91–104. - PubMed
    1. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, et al. Activation of orphan receptors by the hormone relaxin. Science. 2002;295(5555):671–4. - PubMed
    1. Halls ML, Bathgate RA, Summers RJ. Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms. Mol Pharmacol. 2006;70(1):214–26. - PubMed
    1. Bogatcheva NV, Truong A, Feng S, Engel W, Adham IM, Agoulnik AI. GREAT/LGR8 is the only receptor for insulin-like 3 peptide. Mol Endocrinol. 2003;17(12):2639–46. - PubMed

Publication types

MeSH terms

LinkOut - more resources